|Issuer:||PMV PHARMACEUTICALS, INC. (PMVP)|
|Original Submission Date:|
THOMPSON PETER A.
C/O PMV PHARMACEUTICALS, INC.
8 CLARKE DRIVE, SUITE 3 CRANBURY, NJ 08512
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||32.29||2022-06-02||deemed execution date||A||16,333 (a)||2031-06-01||common stock 16,333||$32.29||16,333||direct|
|f1||shares subject to the option vest on the earlier of (i) june 2, 2022 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders.|
|f2||pursuant to an agreement with orbimed advisors llc and orbimed capital gp v llc, the reporting person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to orbimed advisors llc and orbimed capital gp v llc, which will in turn ensure that such securities or economic benefits are provided to orbimed private investments v, lp.|